Pfizer: Pfizer's Subcutaneous PD-1 Cuts Risks in Bladder Cancer but Misses OS Endpoint

Pfizer's sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due to any cause or persistence of cancer cells by 32% in patients with high-risk non-muscle invasive bladder cancer.